What happened with ASMB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Assembly Biosciences is working to bring new medicines for serious viral diseases through laboratory studies and clinical trials. It has no approved products or product-sales revenue, so its business currently relies on collaboration payments rather than sales to patients. Share offerings and strategic collaborations have been its principal sources of funding.
Gilead supplies all of its reported collaboration revenue and holds options to license its drug programs. Gilead has taken an exclusive license to the HPI program, whose further development, manufacturing and commercialization depend on that partner. The arrangement can provide research funding, milestone payments and future royalties, but Gilead can decline other programs. Assembly’s path to drug sales requires successful studies and regulatory approval; it has not yet submitted a marketing application.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Assembly depends on Gilead Sciences for program funding and rights payments: Gilead licenses antiviral programs to Assembly, buys rights to Assembly programs and also develops competing hepatitis B treatments. Gilead supplied all of Assembly’s collaboration revenue in 2025 and 2024, making its decisions to take up programs—such as HPI in December 2025—especially important to watch.
Aligos Therapeutics competes with Assembly in developing hepatitis B treatments, including drugs that alter how the virus’s outer protein shell assembles, called capsid assembly modulators. Its move into a Phase 2 trial, which triggered a $9 million license milestone payment in 2025, is a concrete sign of progress in this competing approach.
Arbutus Biopharma competes with Assembly for chronic hepatitis B patients through its experimental treatments imdusiran and AB-101. Watch whether these programs advance toward controlling the infection without ongoing treatment, the outcome Arbutus aims to support.
Vir Biotechnology’s tobevibart-elebsiran combination competes with Assembly’s candidates to treat chronic hepatitis D. Its ECLIPSE 1, 2 and 3 trials aimed at supporting approval are the relevant developments to watch; Vir retains commercial rights in the United States and international markets outside Greater China, while Norgine holds Europe, Australia and New Zealand.
Precision BioSciences competes with Assembly for hepatitis B patients using a different approach: its PBGENE-HBV program edits genes inside the body. Progress in this wholly owned program is the news most relevant to Assembly’s competing hepatitis B therapies.
GSK and Assembly develop hepatitis B treatments for the same patient population, making GSK’s hepatitis B development progress relevant to Assembly’s competitive position. GSK earns revenue from medicines and vaccines, but its hepatitis B treatment news is the part to watch for this tie.
Mirum Pharmaceuticals and Assembly compete in developing treatments for chronic viral hepatitis, including hepatitis D. Mirum already sells medicines for other liver-related diseases, but its hepatitis D program progress—not sales of those marketed medicines—is the news most directly relevant to this rivalry.
GSK plc earningsGSK
GSK’s report will show how its hepatitis B program is progressing, revealing how directly it is competing with Assembly Biosciences for the same patients.
Watch whether GSK reports progress in its hepatitis B program or delays and setbacks. Progress would mean stronger competition for Assembly Biosciences’ potential patients; a setback would ease that pressure for now, but would not show whether Assembly’s own treatments work.
Gilead Sciences Inc earningsGILD
Gilead Sciences funds Assembly Biosciences through collaborations and competes for hepatitis B patients, so its report can show both the support and competitive pressure Assembly faces.
Separate Gilead Sciences’ reported program progress, collaboration arrangements or payments from its progress in competing hepatitis B treatments. Continued collaboration support can help Assembly Biosciences fund development and rely less on its own cash; weaker support could increase its financing needs, while faster progress in Gilead’s competing program would add pressure for Assembly. Gilead’s results alone do not establish how much revenue Assembly recognized.
Vir Biotechnology, Inc. earningsVIR
Vir Biotechnology’s report will show progress in trials of its chronic hepatitis D combination treatment, indicating how much competition Assembly Biosciences’ hepatitis D candidates may face.
Watch whether Vir Biotechnology’s ECLIPSE trials advance toward supporting approval or encounter delays and setbacks. Progress would bring a competing treatment closer to patients and intensify competition for Assembly Biosciences’ hepatitis D programs; delays would ease that pressure for now, but would not establish that Assembly’s candidates will succeed.
Assembly Biosciences, Inc earningsThis company
Assembly Biosciences has no approved drugs and relies on collaboration income and financing to advance its pipeline; this report will show whether collaboration income is keeping pace with development costs.
Read collaboration revenue alongside research and development costs and cash used in operations. If collaboration income keeps pace with pipeline spending, partner funding is helping Assembly advance its programs; if income falls short while cash use continues, Assembly still has to rely on its reserves or raise more capital to keep the pipeline moving.
